CRISPR Gene Editing in Neurodegeneration

Introduction

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated nucleases (such as Cas9) represent one of the most transformative technologies in modern biomedical research. As programmable genome-editing systems, they hold major translational potential for neurodegenerative diseases. CRISPR approaches are being explored to model disease biology, silence toxic gain-of-function alleles, and correct pathogenic variants in genes implicated in [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and [Huntington's Disease](/diseases/huntingtons)[@doudna2014].

The development of CRISPR-Cas9 technology has revolutionized genetic engineering by providing a simple, efficient, and versatile method for editing genomes. Unlike previous gene-editing approaches that required custom-engineered nucleases for each target, CRISPR uses a short guide RNA to direct the Cas9 enzyme to any genomic sequence with a protospacer adjacent motif (PAM). This simplicity has accelerated the application of gene editing to previously intractable biological questions and therapeutic targets[@jinek2012].

Overview

Introduction

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated nucleases (such as Cas9) represent one of the most transformative technologies in modern biomedical research. As programmable genome-editing systems, they hold major translational potential for neurodegenerative diseases. CRISPR approaches are being explored to model disease biology, silence toxic gain-of-function alleles, and correct pathogenic variants in genes implicated in [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and [Huntington's Disease](/diseases/huntingtons)[@doudna2014].

The development of CRISPR-Cas9 technology has revolutionized genetic engineering by providing a simple, efficient, and versatile method for editing genomes. Unlike previous gene-editing approaches that required custom-engineered nucleases for each target, CRISPR uses a short guide RNA to direct the Cas9 enzyme to any genomic sequence with a protospacer adjacent motif (PAM). This simplicity has accelerated the application of gene editing to previously intractable biological questions and therapeutic targets[@jinek2012].

Overview

The canonical CRISPR-Cas9 system uses a single guide RNA (sgRNA) to direct the Cas9 endonuclease to a complementary genomic target flanked by a protospacer adjacent motif (PAM). Cas9 introduces a double-strand break (DSB) at the target site, which the cell repairs through either non-homologous end joining (NHEJ) — often resulting in insertions or deletions (indels) that disrupt gene function — or homology-directed repair (HDR), which can introduce precise sequence changes when a donor template is provided[@jinek2012].

For neurodegenerative diseases, NHEJ-mediated gene disruption is used to silence toxic gain-of-function alleles, while HDR enables correction of point mutations in genes such as [APP](/genes/app), [PSEN1](/genes/psen1), [SOD1](/proteins/sod1-protein), and [HTT](/genes/htt)[@komor2016]. The ability to precisely modify the genome has opened new avenues for understanding disease mechanisms and developing therapies.

Historical Development

The CRISPR-Cas9 system was adapted from bacterial adaptive immune systems, where it provides protection against viral and plasmid DNA. Key milestones include:

• 2012: Jinek et al. demonstrate that Cas9 can be programmed with guide RNAs to cleave specific DNA sequences[@jinek2012]
• 2013: Multiple groups report successful CRISPR-Cas9 editing in mammalian cells
• 2014: Doudna and Charpentier publish the foundational paper on CRISPR-Cas9 as a genome engineering tool[@doudna2014]
• 2016: Base editors are developed, enabling single-nucleotide conversions without double-strand breaks[@komor2016]
• 2019: Prime editors enable all 12 types of point mutations plus insertions and deletions[@anzalone2019]
• 2021: First FDA-approved CRISPR therapy (Casgevy) for sickle cell disease

Mechanism of Action

CRISPR-Cas9 Nuclease System

The canonical CRISPR-Cas9 system operates through a coordinated mechanism:

• Non-homologous end joining (NHEJ): Error-prone repair that often results in small insertions or deletions (indels), disrupting gene function
• Homology-directed repair (HDR): Precise repair using a donor DNA template, enabling exact sequence modifications

Next-Generation Editing Tools

Second-generation CRISPR technologies have addressed key limitations of nuclease-based editing[@anzalone2019]:

Base Editors: Cytosine and adenine base editors enable direct conversion of one nucleotide to another without creating DSBs, reducing the risk of large deletions and chromosomal rearrangements. Cytosine base editors (CBEs) convert C→T, while adenine base editors (ABEs) convert A→G. These tools are particularly valuable for correcting point mutations that cause neurodegenerative diseases.

Prime Editors: Using a Cas9 nickase fused to an engineered reverse transcriptase, prime editors allow all 12 possible point mutations plus small insertions and deletions without DSBs or donor templates. This represents the most versatile CRISPR editing approach to date[@anzalone2019].

CRISPRi/CRISPRa: Catalytically dead Cas9 (dCas9) fused to transcriptional repressors or activators enables reversible modulation of gene expression without permanent genome modification. This is particularly attractive for the central nervous system where irreversible changes carry heightened risk.

CRISPR Diagnostic Tools: Beyond editing, CRISPR systems like SHERLOCK and DETECTR have been adapted for highly sensitive detection of nucleic acids, potentially useful for biomarker detection in neurodegenerative diseases.

Applications in Neurodegenerative Diseases

Alzheimer's Disease

CRISPR approaches for [Alzheimer's Disease](/diseases/alzheimers-disease) target multiple pathological pathways[@park2019]:

Amyloid Precursor Protein Processing: Disruption of the [BACE1](/proteins/bace1-protein) gene, which cleaves [APP](/genes/app) to generate amyloid-beta, has shown reduced amyloid-beta production in mouse models. CRISPR-mediated BACE1 knockout reduces amyloid plaque formation and improves cognitive function in AD mouse models[@park2019].

APOE Variants: CRISPR-based conversion of the [APOE](/proteins/apoe-protein) ε4 allele to the protective ε3 variant represents a potential therapeutic approach. The APOE ε4 allele is the strongest genetic risk factor for late-onset AD, and converting it to ε3 could reduce amyloid pathology.

Presenilin Mutations: For familial AD caused by [PSEN1](/genes/psen1) and [PSEN2](/genes/psen2) mutations, prime editing offers the precision needed to correct over 300 known pathogenic variants while preserving normal presenilin function[@didiano2024].

APP Mutations: CRISPR base editing has been used to correct pathogenic APP mutations in cellular models, demonstrating the potential for precision therapy in AD[@kim2020].

Parkinson's Disease

In [Parkinson's Disease](/diseases/parkinsons-disease), CRISPR targets include multiple genes implicated in disease pathogenesis[@kantor2018]:

SNCA Gene: The [SNCA](/genes/snca) gene encoding alpha-synuclein, whose duplication, triplication, or missense mutations (A53T, A30P, E46K) cause autosomal dominant PD. CRISPRi-mediated silencing of SNCA reduces alpha-synuclein expression and aggregation in dopaminergic neurons of the substantia nigra, the population most vulnerable in PD[@kantor2018].

LRRK2 Mutations: CRISPR has been used to correct the [LRRK2](/proteins/lrrk2-protein) G2019S mutation, the most common genetic cause of familial PD, in patient-derived iPSC models. Correction of this mutation rescues mitochondrial dysfunction in dopaminergic neurons.

PINK1 and PRKN: Knockout of [PINK1](/proteins/pink1-protein) and [PRKN](/genes/prkn) via CRISPR has generated improved cellular models for studying mitochondrial dysfunction in PD. These genes are implicated in mitophagy, and their dysfunction leads to accumulation of damaged mitochondria.

GBA Mutations: CRISPR approaches are being developed to correct [GBA](/genes/gba) mutations, which represent a significant genetic risk factor for PD, particularly in Ashkenazi Jewish populations.

Amyotrophic Lateral Sclerosis

For [ALS](/diseases/amyotrophic-lateral-sclerosis), CRISPR-mediated gene editing shows significant therapeutic potential[@gaj2017]:

SOD1 Mutations: CRISPR-mediated disruption of mutant [SOD1](/proteins/sod1-protein) has shown striking efficacy in transgenic mouse models, extending survival by up to 25% when delivered via adeno-associated virus (AAV) vectors[@gaj2017]. Over 200 SOD1 mutations cause familial ALS, making this a major therapeutic target.

C9orf72 Hexanucleotide Repeat Expansion: The most common genetic cause of both familial ALS and frontotemporal dementia (FTD). CRISPR excision of the expanded repeat or CRISPRi-mediated silencing of the sense and antisense transcripts that produce toxic dipeptide repeat proteins has shown promise in cellular models[@li2024].

FUS and TARDBP Mutations: CRISPR editing of [FUS](/genes/fus) and [TARDBP](/genes/tardbp) (encoding TDP-43) mutations has been explored in iPSC-derived motor neurons, demonstrating that correction of these mutations can rescue neuronal pathology.

C9orf72 Targeting: CRISPR-Cas9 mediated targeting of the C9orf72 repeat expansion represents a promising approach to reduce both the sense and antisense toxic transcripts[@li2024].

Huntington's Disease

[Huntington's Disease](/diseases/huntingtons), caused by CAG trinucleotide repeat expansion in the [HTT](/genes/htt) gene, is a prime candidate for CRISPR therapy because it follows a monogenic, autosomal dominant inheritance pattern[@shin2016]:

Allele-Selective Editing: Allele-selective CRISPR strategies target single-nucleotide polymorphisms (SNPs) linked to the expanded allele, preserving normal huntingtin function while eliminating the toxic mutant protein[@shin2016].

Promoter Targeting: In HD mouse models, AAV-delivered CRISPR targeting the HTT promoter region with CRISPRi has achieved sustained reduction of mutant huntingtin levels with accompanying behavioral improvement[@chen2023].

Repeat Expansion Targeting: Direct targeting of the CAG repeat using CRISPR systems has shown promise in reducing mutant huntingtin expression.

Delivery to the Central Nervous System

Effective delivery of CRISPR components across the blood-brain barrier remains one of the greatest challenges for clinical translation[@wang2020]:

Viral Vectors

AAV Vectors: Adeno-associated viruses, particularly AAV9 and AAVrh10, can transduce neurons and astrocytes after intrathecal or intravenous injection. However, AAV has a limited cargo capacity (~4.7 kb), which is insufficient for SpCas9 plus its sgRNA in a single vector[@wang2020]. Solutions include:

• Split-intein approaches: Splitting Cas9 into two parts that reconstitute after translation
• Smaller Cas orthologs: SaCas9, CjCas9, and Cas12a have smaller coding sequences

Non-Viral Delivery

Lipid Nanoparticles (LNPs): Offer non-viral delivery with reduced immunogenicity and the ability to carry larger payloads, including mRNA encoding Cas9 and the sgRNA[@suh2024]. LNPs can be surface-functionalized with targeting moieties to cross the blood-brain barrier.

Exosomes and Extracellular Vesicles: Engineered exosomes represent emerging delivery platforms that exploit natural membrane-trafficking pathways to cross the blood-brain barrier[@akyuz2024].

Direct Brain Injection: Stereotactic injection into specific brain regions (e.g., hippocampus, striatum) provides localized delivery but is invasive and impractical for diffuse diseases like AD.

Delivery Challenges

The central nervous system presents unique delivery challenges:

• Blood-brain barrier: Most delivery systems must either cross or bypass the BBB
• Cell-type specificity: Targeting specific neuronal populations while avoiding others
• Scalability: Achieving uniform editing across billions of neurons
• Duration of expression: Balancing therapeutic benefit with avoiding long-term immune responses

Challenges and Safety Considerations

Off-Target Effects

Unintended editing at genomic sites similar to the target sequence remains a critical concern, especially for irreversible applications in the brain[@wang2020]:

• High-fidelity Cas9 variants: eSpCas9 and HiFi-Cas9 reduce off-target activity
• Truncated sgRNAs: Shorter guide RNAs decrease off-target effects while maintaining on-target efficiency
• Unbiased detection: GUIDE-seq and CIRCLE-seq enable comprehensive profiling of off-target sites
• Whole-genome sequencing: Required before clinical translation to ensure safety

Immunogenicity

Bacterial-derived Cas proteins elicit humoral and cellular immune responses in humans[@charlesworth2019]:

• Pre-existing immunity: Anti-Cas9 antibodies detected in 58-79% of the human population
• T-cell responses: Can eliminate edited cells, reducing therapeutic efficacy
• Mitigation strategies: Transient mRNA delivery, immunosuppressive regimens, and engineered Cas orthologs

Mosaicism and Editing Efficiency

Achieving uniform editing across the billions of neurons in the human brain is not feasible with current technology[@charlesworth2019]:

• Therapeutic threshold: Strategies must focus on diseases where partial reduction (50-70%) is sufficient for clinical benefit
• Regional targeting: Localized editing within specific vulnerable brain regions may be sufficient
• Iterative treatment: Multiple dosing may be needed to achieve therapeutic effect

Ethical Considerations

Germline editing for neurodegenerative diseases raises fundamental ethical questions[@frangoul2021]:

• Heritability: Changes to germline DNA are passed to future generations
• Consent: Future generations cannot consent to genetic modifications
• Equitable access: Ensuring fair distribution of expensive therapies
• Regulatory frameworks: Current consensus restricts clinical applications to somatic editing

Current Research and Clinical Pipeline

As of 2025, no CRISPR-based therapy has entered clinical trials for neurodegenerative diseases, though several preclinical programs are advancing rapidly:

Preclinical Programs

• Intellia Therapeutics: Developing in vivo CRISPR platforms for CNS targets
• CRISPR Therapeutics: Advancing AAV-delivered CRISPR for neurological indications
• Multiple academic groups: Working on delivery optimization and disease-specific applications

Regulatory Pathway

The success of CRISPR-based therapies in other domains demonstrates feasibility[@frangoul2021]:

• Casgevy (exagamglogene autotemcel): FDA-approved CRISPR therapy for sickle cell disease
• Other approvals: CRISPR therapies for beta-thalassemia and other conditions
• Regulatory precedent: These approvals provide a pathway for neurodegeneration applications

Timeline Projections

Ongoing advances in delivery technology, editing precision, and biomarker-guided patient selection are expected to bring the first neurodegeneration CRISPR trials to the clinic within the next 3-5 years. Key milestones include:

• Improved AAV capsids for CNS targeting
• Clinical validation of non-viral delivery systems
• Patient selection biomarkers for genetic subtypes
• Long-term safety studies in relevant animal models

Comparative Analysis

CRISPR vs. Other Gene Therapy Approaches

| Approach | Advantages | Limitations |
|----------|------------|--------------|
| CRISPR-Cas9 | Versatile, efficient, relatively simple | Off-target effects, immunogenicity |
| Base Editing | Precise single-nucleotide changes | Limited to C→T and A→G conversions |
| Prime Editing | All 12 types of point mutations | Larger cargo requirements |
| Antisense Oligonucleotides | Well-established CNS delivery | Requires repeated dosing |
| RNAi | Reversible gene silencing | Off-target effects possible |

CRISPRi vs. CRISPR-Cas9

For neurodegenerative diseases, CRISPRi (interference) offers advantages over permanent CRISPR-Cas9 editing:

• Reversibility: Can be turned off if adverse effects occur
• Tunable: Expression levels can be adjusted
• Reduced immunogenicity: dCas9 is less likely to trigger immune responses
• Safety: No permanent genome modifications

Future Directions

Emerging Technologies

CRISPR Diagnostics: Highly sensitive detection of neurodegenerative disease biomarkers using CRISPR-based detection systems. These could enable early diagnosis and disease monitoring.

Epigenetic Editing: Using catalytically dead Cas9 fused to epigenetic modifiers to alter gene expression without changing the DNA sequence. This approach could modulate disease-associated genes reversibly.

Multiplexed Editing: Simultaneous targeting of multiple genes using multiple guide RNAs. This is particularly relevant for complex diseases like AD where multiple pathways are affected.

Therapeutic Pipeline

The most advanced CRISPR programs for neurodegenerative diseases are expected to focus on:

Combination Approaches

Future therapies may combine CRISPR with other modalities:

• Gene therapy + small molecules: CRISPR correction combined with symptomatic treatment
• CRISPR + cell therapy: Edited cells transplanted into the CNS
• CRISPR + neuroprotection: Gene editing combined with neurotrophic factor delivery

Conclusion

CRISPR gene editing represents a transformative technology with significant potential for treating neurodegenerative diseases. The ability to precisely modify genetic sequences offers hope for diseases that have been largely untreatable at their root cause. However, significant challenges remain, including delivery to the central nervous system, off-target effects, and immunogenicity.

The field is advancing rapidly, with next-generation editing tools (base editors, prime editors, CRISPRi) providing safer and more precise alternatives to original CRISPR-Cas9. While no CRISPR therapy has yet reached clinical trials for neurodegenerative diseases, the success of CRISPR in other areas provides a clear pathway forward.

The next 3-5 years will be critical for translating preclinical findings into clinical applications. Key advances in delivery technology, patient selection, and safety validation will determine when and how CRISPR therapies become available for patients with Alzheimer's Disease, Parkinson's Disease, ALS, and Huntington's Disease.

Conclusion

CRISPR gene editing represents a transformative technology with significant potential for treating neurodegenerative diseases. The ability to precisely modify genetic sequences offers hope for diseases that have been largely untreatable at their root cause. However, significant challenges remain, including delivery to the central nervous system, off-target effects, and immunogenicity.

The field is advancing rapidly, with next-generation editing tools (base editors, prime editors, CRISPRi) providing safer and more precise alternatives to original CRISPR-Cas9. While no CRISPR therapy has yet reached clinical trials for neurodegenerative diseases, the success of CRISPR in other areas provides a clear pathway forward.

The next 3-5 years will be critical for translating preclinical findings into clinical applications. Key advances in delivery technology, patient selection, and safety validation will determine when and how CRISPR therapies become available for patients with Alzheimer's Disease, Parkinson's Disease, ALS, and Huntington's Disease.

See Also

• [Antisense Oligonucleotides](/technologies/antisense-oligonucleotides)](/technologies)
• [Brain Organoids](/technologies/brain-organoids)](/technologies)
• [iPSC Disease Models](/technologies/ipsc-disease-models)](/technologies)
• [Gene Therapy](/therapeutics/gene-therapy)](/therapeutics)
• [AAV Gene Therapy](/therapeutics/aaiv-gene-therapy)](/therapeutics)
• [AI in Neurodegeneration](/technologies/ai-neurodegeneration)